Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 3/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13868646 | 0.94 | PRKDC (0.36) | RAB9APRKDCAKT1KDM4EALDH1A1 | |
| SCHEMBL13868657 | 0.92 | MAPT (0.35) | RAB9APRKDCAKT1KDM4EALDH1A1 | |
| SCHEMBL13868669 | 0.91 | TTK (0.33) | RAB9APRKDCAKT1KDM4EALDH1A1 | |
| SCHEMBL12189458 | 0.90 | PRKDC (0.33) | RAB9APRKDCAKT1KDM4EALDH1A1 | |
| SCHEMBL10262462 | 0.90 | PRKDC (0.34) | PRKDCAKT1KDM4EALDH1A1LMNA | |
| SCHEMBL10292860 | 0.90 | PRKDC (0.34) | RAB9APRKDCAKT1KDM4EALDH1A1 | |
| SCHEMBL10267980 | 0.90 | PRKDC (0.34) | PRKDCAKT1KDM4EALDH1A1LMNA | |
| SCHEMBL13868630 | 0.90 | PRKDC (0.34) | PRKDCAKT1KDM4EALDH1A1LMNA | |
| SCHEMBL10262395 | 0.90 | PRKDC (0.34) | PRKDCAKT1KDM4EALDH1A1LMNA | |
| SCHEMBL13868628 | 0.90 | PRKDC (0.34) | RAB9APRKDCAKT1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521004-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| US-7521004-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070215844-A1 | Chromene Compound | TOKUYAMA CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070215844-A1 | Chromene Compound | TOKUYAMA CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070215844-A1 | Chromene Compound | CRY2, TYR, CRY1 | RAB9A 2789/4885PRKDC 3723/4885DGAT1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.